Nuvo Research Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario as Clark Pharmaceutical Laboratories Ltd. On November 14, 1990, the articles were amended to change the name of the Company from Clark Pharmaceutical Laboratories Ltd. to Dimethaid Research Inc. On September 30, 2005, the articles were further amended to change the name of the Company from Dimethaid Research Inc. to Nuvo Research Inc. On January 1, 2007, the Company completed a short-form amalgamation with Akorn Pharmaceuticals Canada Limited, Excelpharm Inc., Femina Inc., Dimethaid Management Inc. and Dimethaid Manufacturing Inc., certain of its subsidiaries. The amalgamated entity continues as Nuvo Research Inc.
Nuvo Research Inc. has two Canadian locations. Its registered office and principal place of business is its head office located in Mississauga, Ontario. It also operates a manufacturing facility in Varennes, Quebec where it manufactures Pennsaid®.
Nuvo Research AG, Nuvo Manufacturing GmbH and Nuvo Research GmbH
Nuvo’s Immune system regulation business is conducted through Nuvo Research AG (NRAG) and NRAG’s two wholly owned German subsidiaries. In December 2011, Nuvo increased its ownership in
NRAG from 60% to 100% by acquiring the minority interest held by Dr. Kühne.
Nuvo Manufacturing GmbH produces OXO-K993 from its manufacturing facility in Wanzleben and Leipzig based Nuvo Research GmbH (NRG) conducts and coordinates research and development activities related to WF10 in collaboration with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig. NRG has received funding commitments for certain of its research and development projects from the Development Bank of Saxony.
ZARS Pharma, Inc.
On May 12, 2011, Nuvo acquired all of the outstanding securities of ZARS Pharma, Inc. (ZARS), through the merger of its wholly owned subsidiary, Nuvo
Research Delaware Inc. (Newco) with and into ZARS, with ZARS as the surviving corporation. ZARS is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily
for the treatment of pain, using its proprietary drug delivery technologies.
ZARS (UK) Limited
ZARS (UK) Limited is incorporated in the United Kingdom and
holds the Pliaglis Marketing Authorization Application that was
submitted in the European Union. ZARS (UK) Limited is a wholly
owned subsidiary of ZARS.
Nuvo Research US, Inc.
Nuvo Research US, Inc. consists primarily of the West Chester, Pennsylvania based Pain Group
operations and management team.
Nuvo Research US, Inc. also included the San Diego research facility which
wound down operations in early 2011.
The Company has maintained the majority of its capabilities and technology by relocating key equipment
from the research facility to other Nuvo
Nuvo Research America, Inc.
In July 2011, Nuvo Research America, Inc. (Nuvo America) was incorporated in the
State of Delaware as a wholly owned subsidiary of Nuvo Research Inc. In
December 2011, Nuvo completed transactions that transferred ownership of wholly
owned subsidiaries, Nuvo US and ZARS to Nuvo America in exchange for additional
shares of Nuvo America.
Dimethaid (UK) Limited
Dimethaid (UK) Limited is a British company, incorporated in 1999, that holds the marketing
authorization for Pennsaid® in the United Kingdom.
Dimethaid Immunology Inc.
In June 1993, Dimethaid Immunology was incorporated as a wholly owned subsidiary of the
Company. It was responsible for the Canadian marketing and distribution of WF10, an aqueous
solution of Oxo-K993 containing stabilized chlorite ions, as well as related products developed by Oxo Chemie. Oxo Chemie
(now Nuvo Research AG) was purchased
by the Company in May 2002. Dimethaid Immunology Inc. currently has limited activity since
WF10 and related products are not currently approved for sale in Canada.